Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

665
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
665
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

387
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
387
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

468
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
468

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haemophilia: Novel Therapies and Diagnostic Challenges.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2026
Same author

Expanding Horizons in Thrombosis and Hemostasis: From Molecular Determinants to Real-World and Expert Opinion Evidence.

Hamostaseologie·2026
Same author

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026
Same author

From Case Reports to Cohort Studies: The Many Faces of Clinical Research in Thrombosis and Haemostasis.

Hamostaseologie·2026
Same author

Proof of concept for aqueous two-phase system-based extraction of cell-free DNA from plasma for liquid biopsy applications.

Scientific reports·2026
Same author

Ageing with Haemophilia: Comorbidities in Focus.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2026

Related Experiment Video

Updated: Apr 4, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.4K

[Anticoagulation in critical care].

Bernd Pötzsch1,2, Hannah L McRae3, Heiko Rühl3

  • 1Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Bonn, Deutschland. bernd.poetzsch@ukbonn.de.

Medizinische Klinik, Intensivmedizin Und Notfallmedizin
|April 2, 2026
PubMed
Summary
This summary is machine-generated.

Intensive care anticoagulation requires personalized management due to bleeding risks. Unfractionated heparin is preferred for treating thromboembolism, while argatroban is used for heparin-induced thrombocytopenia.

Keywords:
Drug monitoringHemorrhageHeparinPrevention and controlThrombosis

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

9.5K

Related Experiment Videos

Last Updated: Apr 4, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.4K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

9.5K

Area of Science:

  • Intensive care medicine
  • Pharmacology
  • Hematology

Background:

  • Anticoagulation is crucial in intensive care for preventing and treating thromboembolism.
  • This patient population has an elevated bleeding risk, necessitating individualized anticoagulant strategies.
  • Management includes careful selection and dose adjustment of anticoagulants.

Purpose of the Study:

  • To review anticoagulant selection and management in intensive care.
  • To highlight the roles of unfractionated heparin and argatroban.
  • To discuss the advantages and monitoring of these agents.

Main Methods:

  • Literature review of anticoagulation in intensive care settings.
  • Comparison of unfractionated heparin and low-molecular-weight heparins for thromboprophylaxis and treatment.
  • Evaluation of direct thrombin inhibitors like argatroban for specific indications.

Main Results:

  • Low-molecular-weight heparins show equivalence or superiority to unfractionated heparin for thromboprophylaxis.
  • Unfractionated heparin is preferred for thromboembolism treatment due to its short half-life, monitorability (activated partial thromboplastin time), and rapid reversal.
  • Argatroban is a key reserve anticoagulant for heparin-induced thrombocytopenia, offering a short half-life, hepatic clearance, and activated partial thromboplastin time monitoring.

Conclusions:

  • Personalized anticoagulation management is essential in intensive care.
  • Unfractionated heparin offers distinct advantages for treating thromboembolism.
  • Argatroban provides a vital alternative for patients with heparin-induced thrombocytopenia.